ArticleBiotechnology and applied biochemistry2025
The Stem Cell Transcription Factor OCT4 Silences Target DNA Methyltransferase 1 to Strengthen DNA Damage Response in Cisplatin-Treated Gastric Cancer Cells.
Article in Biotechnology and applied biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Stem Cell Transcription Factor OCT4 Silences Target DNA Methyltransferase 1 to Strengthen DNA Damage Response in Cisplatin-Treated Gastric Cancer Cells.Biotechnology and applied biochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
OCT4 plays a crucial role in the DNA damage response(DDR) mechanism, whereas cisplatin (CDDP) acts as an anti-tumor agent by inducing DDR. This study aimed to investigate the role of OCT4 in regulating DNA methyltransferase 1 (DNMT1) in CDDP-treated gastric cancer (GC). A dual-luciferase reporter assay was performed to detect the relationship between DNMT1 and OCT4. Human GC cell lines HGC-27 and MGC-803 were transfected with siRNA-OCT4 or ov-DNMT1 to construct interfering cell lines; CDDP of 0, 2.5, 5, 10, and 20 µM was used to treat GC cell lines, respectively. As follows, γ-H2AX immunofluorescence was used to detect DDR. The protein expressions of OCT4 and DNMT1 were detected by Western blot (WB), and the effects of CDDP treatment on cell apoptosis and proliferation were assessed using CCK8, cell cloning, and flow cytometry. The IC50 of CDDP-treated GC cells was reduced by OCT4 silence but enhanced by DNMT1 overexpression. A targeted regulatory relationship exists between OCT4 and DNMT1. The expression of OCT4 and DNMT1 was increased in CDDP-treated cells, and DNMT1 was decreased in the siRNA-OCT4 group. In the CDDP-treated GC cells, DNMT1 overexpression significantly reversed the siRNA-OCT4-induced cell apoptosis, γ-H2AX upregulation, and proliferation decrease. OCT4 silence may target DNMT1 to induce DDR in GC cells to strengthen the CDDP-induced cell apoptosis and proliferation inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.